[go: up one dir, main page]

ES2087237T3 - Progestogeno como unico contraceptivo. - Google Patents

Progestogeno como unico contraceptivo.

Info

Publication number
ES2087237T3
ES2087237T3 ES91203328T ES91203328T ES2087237T3 ES 2087237 T3 ES2087237 T3 ES 2087237T3 ES 91203328 T ES91203328 T ES 91203328T ES 91203328 T ES91203328 T ES 91203328T ES 2087237 T3 ES2087237 T3 ES 2087237T3
Authority
ES
Spain
Prior art keywords
regime
ketodesogestrel
desogestrel
progestogen
oral contraceptive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91203328T
Other languages
English (en)
Inventor
Bennink Herman Jan Ti Coelingh
Engelbert Willem Bergink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8205203&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2087237(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Application granted granted Critical
Publication of ES2087237T3 publication Critical patent/ES2087237T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

SE DESCRIBE UN REGIMEN ANTICONCEPTIVO ORAL QUE CONTIENE UNIDADES DE DOSIFICACION DIARIAS CADA UNA DE LAS CUALES CONTIENE ENTRE 70 Y 80 MICROGRAMOS DE DESOGESTREL, 3-KETODESOGESTREL O SUS MEZCLAS. SE HA ENCONTRADO QUE HACIENDO UNA SELECCION DE DESOGESTREL O 3-KETODESOGESTREL EN LAS DOSIS DESCRITAS EN UN REGIMEN ANTICONCEPTIVO ORAL ADMINISTRADO A LO LARGO DEL CICLO MENSTRUAL COMPLETO (P.EJ. 28 DIAS), SE CONSIGUE UNA INHIBICION DE OVULACION EFECTIVA Y SE EVITA UNA HEMORRAGIA INTERMENSTRUAL , MIENTRAS SE MANTIENE UN CONTROL DEL CICLO ACEPTABLE. ADEMAS, EL REGIMEN EVITA TAMBIEN LA FORMACION DE QUISTES OVARICOS PERSISTENTES.
ES91203328T 1990-12-17 1991-12-12 Progestogeno como unico contraceptivo. Expired - Lifetime ES2087237T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP90203371 1990-12-17

Publications (1)

Publication Number Publication Date
ES2087237T3 true ES2087237T3 (es) 1996-07-16

Family

ID=8205203

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91203328T Expired - Lifetime ES2087237T3 (es) 1990-12-17 1991-12-12 Progestogeno como unico contraceptivo.

Country Status (20)

Country Link
US (1) US5461041A (es)
EP (1) EP0491443B1 (es)
JP (1) JPH04290829A (es)
KR (1) KR100221008B1 (es)
CN (1) CN1036834C (es)
AT (1) ATE135218T1 (es)
AU (1) AU649082B2 (es)
CA (1) CA2057714C (es)
DE (2) DE69117902T2 (es)
DK (1) DK0491443T3 (es)
ES (1) ES2087237T3 (es)
FI (1) FI98984C (es)
GR (1) GR3020180T3 (es)
IE (1) IE71202B1 (es)
LU (1) LU90341I2 (es)
NL (1) NL990003I2 (es)
NO (2) NO2002013I2 (es)
NZ (1) NZ240969A (es)
PT (1) PT99818B (es)
ZA (1) ZA919732B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4133680A1 (de) * 1991-10-11 1993-04-15 Metallgesellschaft Ag Stabilisierte staerke, verwendung der stabilisierten staerke und verfahren zu ihrer herstellung
DE4227989A1 (de) * 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
US5395627A (en) * 1992-09-04 1995-03-07 Akzo N.V. Pharmaceutical granulate
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
ZA949929B (en) * 1993-12-23 1995-08-23 Akzo Nobel Nv Sugar-coated pharmaceutical dosage unit.
DE4405590C1 (de) * 1994-02-22 1995-07-20 Hesch Rolf Dieter Prof Dr Med Mittel zur postmenopausalen Hormonbehandlung
KR100384264B1 (ko) * 1994-09-22 2003-08-30 악조 노벨 엔.브이. 습식과립화에의한 투여단위의제조방법
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
AU4134599A (en) * 1998-04-07 1999-10-25 Akzo Nobel N.V. Progestogen-only contraceptive kit
AU5619399A (en) * 1998-08-11 2000-03-06 Akzo Nobel N.V. Progestogen-only contraceptive kit providing good cycle control
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20050113351A1 (en) * 2000-03-21 2005-05-26 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20040176336A1 (en) * 2000-03-21 2004-09-09 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
GB0114746D0 (en) 2001-06-16 2001-08-08 Boots Co Plc Medicinal composition
US6574033B1 (en) 2002-02-27 2003-06-03 Iridigm Display Corporation Microelectromechanical systems device and method for fabricating same
TW200403075A (en) * 2002-05-29 2004-03-01 Akzo Nobel Nv Progestagenic dosage units
JP5207432B2 (ja) * 2003-04-29 2013-06-12 エム・エス・ディー・オス・ベー・フェー アンチ溶媒凝固プロセス
DE102005053771A1 (de) * 2005-11-09 2007-05-10 Grünenthal GmbH Darreichform zur hormonalen Kontrazeption
DE202010010589U1 (de) 2010-07-22 2010-10-14 Bayer Schering Pharma Aktiengesellschaft Estrogenfreie Formulierung zur oralen Kontrazeption, bevorzugt verwendbar für Frauen mit bewusster/unbewusster Laktoseintoleranz oder mit bewusster laktosefreier Kontrazeption
EP2730284A1 (en) * 2012-11-12 2014-05-14 Naari AG Levonorgestrel-only-composition for optimized oral contraception with defined levonorgestrel content, dosage regimen and pharmaceutical preparation
US10441591B2 (en) 2015-06-30 2019-10-15 Shanghai Jiao Tong University Applications for etonogestrel in preparing anti-prostate cancer products
US11679114B2 (en) 2021-07-26 2023-06-20 Navad Life Sciences Pte Progestogen-only oral contraception

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4066757A (en) * 1973-03-26 1978-01-03 Ortho Pharmaceutical Corporation Oral contraceptive regimen
DE3879031T2 (de) * 1987-08-08 1993-06-24 Akzo Nv Kontrazeptives implantat.

Also Published As

Publication number Publication date
NZ240969A (en) 1994-04-27
US5461041A (en) 1995-10-24
IE914271A1 (en) 1992-06-17
FI915913A0 (fi) 1991-12-16
KR920011514A (ko) 1992-07-24
NL990003I2 (nl) 1999-05-03
FI98984C (fi) 1997-09-25
GR3020180T3 (en) 1996-09-30
PT99818B (pt) 1999-05-31
CA2057714C (en) 2002-10-01
NO2002013I2 (no) 2007-02-26
FI98984B (fi) 1997-06-13
NO914970L (no) 1992-06-18
NO178686B (no) 1996-02-05
CN1036834C (zh) 1997-12-31
PT99818A (pt) 1992-11-30
AU8967891A (en) 1992-06-18
JPH04290829A (ja) 1992-10-15
EP0491443A1 (en) 1992-06-24
DE69117902D1 (de) 1996-04-18
NO178686C (no) 1996-05-15
FI915913L (fi) 1992-06-18
LU90341I2 (fr) 1999-03-29
ATE135218T1 (de) 1996-03-15
DE19975011I2 (de) 2005-05-04
ZA919732B (en) 1992-09-30
AU649082B2 (en) 1994-05-12
DE69117902T2 (de) 1996-08-29
KR100221008B1 (ko) 1999-09-15
CA2057714A1 (en) 1992-06-18
CN1062465A (zh) 1992-07-08
NO914970D0 (no) 1991-12-16
NL990003I1 (nl) 1999-04-01
EP0491443B1 (en) 1996-03-13
IE71202B1 (en) 1997-02-12
DK0491443T3 (da) 1996-06-24

Similar Documents

Publication Publication Date Title
ES2087237T3 (es) Progestogeno como unico contraceptivo.
ES2087964T3 (es) Contraceptivos orales bajos en estrogenos.
ES2057124T3 (es) Producto terapeutico para el tratamiento de estados peri- o post-menopausicos.
ES2117015T3 (es) Composiciones que contienen sumatriptan.
EP0136011A3 (en) A method of hormonal treatment of peri-menopausal, menopausal and post-menopausal disorders and multi-preparation pack therefor
SE8601709L (sv) Farmaceutiskt medel samt komposition innehallande detta
ES2172592T3 (es) Agente antagonista de progesterona y agente gestageno para el tratamiento de la endometriosis y del liomioma uterino.
ES2181770T3 (es) Formulacion combinada farmaceutical para la contracepcion hormonal.
ES2044147T3 (es) Recipiente para envasar un medicamento.
ES2037086T3 (es) Procedimiento para preparar formulaciones farmaceuticas.
ES2060350T3 (es) Forma de dosificacion por via oral osmotica, para el control de la fertilidad.
ES8605532A1 (es) Un procedimiento para preparar derivados de aminoglicosido
CY1108648T1 (el) Αναστολεας της αρωματασης σε μια δοση για την θεραπευτικη αντιμετωπιση της υπογόνιμοτήτας
ES478048A1 (es) Procedimiento para la obtencion de difenil-imidazolil-meta- nos sustituidos.
ES2059130T3 (es) Composiciones farmaceuticas que contienen ipriflavona, procedimiento para su preparacion y uso terapeutico relacionado.
MX9203361A (es) Composiciones farmaceuticas que contienen cloruro de galio.
MX9304931A (es) Anticonceptivos que contienen antiprogestogenos.
NZ504351A (en) Contraceptive kit comprising progestogen and anti-progestogen and use in treating bleeding induced by a progestogen-only contraceptive regimen
ES294897A1 (es) Mejoras introducidas en la preparación de composiciones farmacéuticas en forma de dosis unitarias
ES2059615T3 (es) Empleo del derivado de tiazol tiprotimoda para la preparacion de un agente para la terapia de infecciones por virus.
AR002946A1 (es) Un conjunto para uso en el tratamiento o la prevencion de la osteoporosis en los mamiferos de acuerdo con una dieta ciclica.
USD235373S (en) Uuluuuiiuuuuuuiiuuuljuuuu-
ES2175086T3 (es) Composiciones farmaceuticas anti-emeticas que contienen metotrimeprazina.
GB1029050A (en) Improvements in and relating to new flavone and the process of preparation and application thereof
BE869172A (fr) Medicament constitue par le methyl-3-acetoxy 2-benzoate d'acetamido-4 phenyle

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 0491443

Country of ref document: ES

SPCF Request for supplementary protection certificate filed

Free format text: DESOGESTREL (CERAZET)

Spc suppl protection certif: C200000009

Filing date: 20000327

SPCG Supplementary protection certificate granted

Free format text: DESOGESTREL (CERAZET)

Spc suppl protection certif: C200000009

Filing date: 20000327

Expiry date: 20121212

Effective date: 20030901